touchONCOLOGY joins Professor Myung-Ju Ahn (Samsung Medical Center, Seoul, South Korea) at WCLC 2021 to discuss the AURA3 trial of osimertinib as a treatment for EGFR-mutant non-small cell lung cancer.
ClinicalTrials.gov Identifier: NCT02151981
1. What are the strengths and limitations of osimertinib as a treatment for EGFR-mutant non-small cell lung cancer? (00:17-01:13)
2. Could you give us a brief overview of the AURA3 clinical trial and its findings? (01:13-02:03)
3. What clinical evidence supports the use of circulating tumour DNA assay as a predictor of clinical response to osimetinib? (02:03-02:47)
4. Could you tell us a little about your analysis and its findings? (02:47-06:27)
5. What is the potential impact of these findings on clinical practice, and what further studies are needed? (06:27-07:45)
Disclosures: Myung-Ju Ahn has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 WCLC Annual Meeting.
Share this Video
Related Videos In Lung Cancer
Sunil Singhal, AACR 2023: Intraoperative molecular imaging as a tool in cancer surgery
Intraoperative molecular imaging enables surgeons to utilise a cancer specific fluorescent dye to improve cancer removal. In this touchONCOLOGY interview, we speak with Dr Sunil Singhal (University of Pennsylvania, Philadelphia, PA, USA) to discuss intraoperative molecular imaging, with focus on its application in lung cancer. The presentation entitled ‘Intraoperative molecular imaging of lung cancer: The […]
Gerard Zalcman, ESMO 2022: IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab in advanced non-small cell lung cancer
First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression […]
Charles Swanton, ESMO 2022: Mechanism of action and an actionable inflammatory axis for air pollution may induce NSCLC in never-smokers
The mechanistic basis for non-small cell lung cancer (NSCLC) initiation in never smokers is unknown. The air pollutant, particulate matter, is known to be associated with the risk of NSCLC, however a direct cause and mechanism remains difficult to achieve. Prof. Charles Swanton (Francis Crick Institute, London, UK) joins touchONCOLOGY to discuss his study into […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!